Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

R8404

Sigma-Aldrich

Rufinamide

≥98% (HPLC), powder

Sinónimos:

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H8F2N4O
Número de CAS:
106308-44-5
Peso molecular:
238.19
MDL number:
MFCD00865314
UNSPSC Code:
12352200
PubChem Substance ID:
24724595
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: 9 mg/mL

originator

Novartis

storage temp.

−20°C

SMILES string

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChI key

POGQSBRIGCQNEG-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem/physiol Actions

Broad-spectrum anticonvulsant.
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Diagnostic Implications

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Carc. 2 - Repr. 2 - STOT SE 3

target_organs

Central nervous system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
106M4613V
124M4601V
021M4615V
056K46204
056K46203

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Emma D Deeks et al.
CNS drugs, 20(9), 751-760 (2006-09-07)
Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures
Paul L McCormack
PharmacoEconomics, 30(3), 247-256 (2012-02-16)
Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy
Marc R Suter et al.
Anesthesiology, 118(1), 160-172 (2012-12-12)
Voltage-gated sodium channels dysregulation is important for hyperexcitability leading to pain persistence. Sodium channel blockers currently used to treat neuropathic pain are poorly tolerated. Getting new molecules to clinical use is laborious. We here propose a drug already marketed as
Rainer Schimpf et al.
Heart rhythm, 9(5), 776-781 (2012-01-17)
The arrhythmogenic potential of short QT intervals has recently been highlighted in patients with a short QT syndrome. Drug-induced QT-interval prolongation is a known risk factor for ventricular tachyarrhythmias. However, reports on drug-induced QT-interval shortening are rare and proarrhythmic effects
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico